Stay updated on ASP1517 Intermittent Dosing in Peritoneal Dialysis Clinical Trial

Sign up to get notified when there's something new on the ASP1517 Intermittent Dosing in Peritoneal Dialysis Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the ASP1517 Intermittent Dosing in Peritoneal Dialysis Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T22:25:26.000Z thumbnail image
  6. Check
    12 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study details related to evaluating the safety and efficacy of ASP1517 in peritoneal dialysis chronic kidney disease patients with anemia.
    Difference
    0.1%
    Check dated 2024-06-06T14:27:13.000Z thumbnail image
  7. Check
    27 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to a detailed description of eligibility criteria, explaining that researchers look for people who fit certain descriptions such as general health condition or prior treatments. This change provides more specific information about the criteria used to select participants for the study.
    Difference
    42%
    Check dated 2024-05-22T21:03:22.000Z thumbnail image
  8. Check
    49 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:32:23.000Z thumbnail image

Stay in the know with updates to ASP1517 Intermittent Dosing in Peritoneal Dialysis Clinical Trial

Enter your email address, and we'll notify you when there's something new on the ASP1517 Intermittent Dosing in Peritoneal Dialysis Clinical Trial page.